ArticleLipids in health and disease2025
Dysbetalipoproteinaemia in genetically predisposed Ghanaians.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysbetalipoproteinaemia (dysβ) is a genetic lipid disorder characterised by accumulated remnant lipoproteins, leading to mixed hyperlipidaemia and increased cardiovascular risk. It is primarily associated with apolipoprotein E (apoE) ε2/ε2 homozygosity, although variants, such as arginine 145 cysteine (R145C), may also contribute. In sub-Saharan Africa, including Ghana, dysβ remains underdiagnosed due to limited awareness and access to diagnostic testing. This study assessed the prevalence of the dysβ phenotype in adult Ghanaians and its association with the apo ε2/ε2 genotype and R145C variant.
methodsA cross-sectional study was conducted among 1,032 Ghanaian adults, comprising healthy controls (n = 702), diabetic patients (n = 268), and patients with ischaemic heart disease (IHD) (n = 62). Anthropometry, blood pressure, and lipid profiles were assessed. LDL particle size and remnant lipoproteins were visualised using polyacrylamide gradient gel electrophoresis (PGGE), while polymerase chain reaction and restriction fragment length polymorphism were used for apoE genotyping. Group comparisons were conducted using chi-square, Kruskal-Wallis and Mann-Whitney U tests.
resultsThe prevalence of dysβ was 1.6%; 4.8% in IHD patients, 1.5% in diabetics and 1.3% in healthy controls (p = 0.80). The ε2/ε2 genotype was identified in 2.6% of participants, with 52% exhibiting the dysβ phenotype. The R145C variant was found in 4.0% of the participants: 6.0% in IHD patients, 5.9% in diabetics, and 2.5% in healthy controls, but none of these carriers developed dysβ. Among healthy controls with ε2/ε2 who had the dysβ phenotype, BMI, WHR, total cholesterol [4.10, IQR (3.27-4.75), and triglycerides [1.08, IQR (0.98-1.54), and lower HDL-C, were statistically comparable to those who did not have the dysβ phenotype.
conclusionThis is the first report of dysβ prevalence in Ghana. Although the phenotype was generally mild, the findings highlight the need for further research into lipid disorders and the role of genetic screening in cardiovascular risk assessment in African nations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.